Dihexa
Dihexa is an angiotensin IV analog reported to be significantly more potent than BDNF at promoting synaptogenesis; people run it for cognitive enhancement and memory improvement, though the captured community corpus is three reports and the formal evidence base remains animal-only with zero human trials. Since community posts lack dose specifics, clinician sources describe oral dosing around 1.25 mg twice daily in the morning, or subcutaneous injections of 2–4 mg, generally on a continuous cycle. There is no FDA-approved indication, and all human use is off-label or compounded.
Research Evidence
Evidence shape
No completed human trials extracted for Dihexa. Animal-model evidence carries the indication cards below.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Dihexa is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
- Frequency
- BID
- Timing
- unspecified
- Route
- oral
- Cycle
- unspecified
Clinician protocols dose 1.3 mg–4 mg BID oral (2 sources).
No structured protocol details captured for this tier yet.
Anecdotal reports primarily highlight Dihexa's use for cognitive enhancement and memory improvement, with 4 community reports indicating 100% positive outcomes for these uses. Specific dosing details are not consistently reported in these anecdotal accounts.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Dihexa, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.